Sugi Predict

Sugi Predict / Compounds / SCHEMBL19348115

SCHEMBL19348115

SCHEMBL19348115

Cc1c(Br)sc2[nH]c(=O)n(C(C)(C)C(=O)OCc3ccccc3)c(=O)c12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 6/20 0.36
▸ RAB9A P51151 4/20 0.35
▸ NPC1 O15118 2/20 0.35
▸ POLB P06746 2/20 0.35
▸ MAPT P10636 1/20 0.35
▸ STAT1 P42224 1/20 0.35
▸ NPSR1 Q6W5P4 1/20 0.35
▸ ATM Q13315 1/20 0.35
▸ MAPK1 P28482 1/20 0.35
▸ SMN1; SMN2 Q16637 1/20 0.35
▸ KMT2A Q03164 2/20 0.34
▸ ADORA2B P29275 1/20 0.34
▸ TDP1 Q9NUW8 1/20 0.34
▸ ACACB O00763 2/20 0.34
▸ MMP1 P03956 1/20 0.33
▸ MMP2 P08253 1/20 0.33
▸ MMP9 P14780 1/20 0.33
▸ MMP12 P39900 1/20 0.33
▸ MEN1 O00255 1/20 0.33
▸ CYP2C9 P11712 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18959819 0.87 RAB9A (0.39) ALDH1A1RAB9ANPC1POLBMAPT
SCHEMBL29072103 0.85 RAB9A (0.35) ALDH1A1RAB9ANPC1POLBMAPT
SCHEMBL18959775 0.85 KMT2A (0.46) ALDH1A1RAB9ANPC1POLBMAPT
SCHEMBL18907373 0.84 ALDH1A1 (0.35) ALDH1A1RAB9ANPC1POLBMAPT
SCHEMBL19361562 0.80 ALDH1A1 (0.38) ALDH1A1MAPTACACB
SCHEMBL19369287 0.80 ALDH1A1 (0.31) ALDH1A1RAB9ANPC1CYP2C9
SCHEMBL14945379 0.80 ACACB (0.32) ALDH1A1POLBKMT2AACACBMEN1
SCHEMBL14945135 0.79 ACACB (0.38) ALDH1A1MAPTACACB
SCHEMBL14945336 0.79 ACACB (0.34) ALDH1A1MAPTACACB
SCHEMBL18914284 0.76 ACACB (0.35) ACACB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4364795-A2 SOLID FORMS OF A THIENOPYRIMIDINEDIONE ACC INHIBITOR AND METHODS FOR PRODUCTION THEREOF Gilead Apollo, LLC (US) 2024-05-08 — — EP disclosed
US-11912718-B2 Solid forms of a thienopyrimidinedione ACC inhibitor and methods for production thereof GILEAD APOLLO, LLC (US) 2024-02-27 — — US disclosed
US-11912718-B2 Solid forms of a thienopyrimidinedione ACC inhibitor and methods for production thereof GILEAD APOLLO, LLC (US) 2024-02-27 — — US disclosed
US-11912718-B2 Solid forms of a thienopyrimidinedione ACC inhibitor and methods for production thereof GILEAD APOLLO, LLC (US) 2024-02-27 — — US disclosed
EP-3423456-B1 SOLID FORMS OF A THIENOPYRIMIDINEDIONE ACC INHIBITOR AND METHODS FOR PRODUCTION THEREOF GILEAD APOLLO LLC (US) 2023-12-27 — — EP disclosed
US-20220064181-A1 SOLID FORMS OF A THIENOPYRIMIDINEDIONE ACC INHIBITOR AND METHODS FOR PRODUCTION THEREOF GILEAD APOLLO, LLC 2022-03-03 — — US disclosed
US-20200148699-A1 SOLID FORMS OF A THIENOPYRIMIDINEDIONE ACC INHIBITOR AND METHODS FOR PRODUCTION THEREOF GILEAD APOLLO, LLC 2020-05-14 — — US disclosed
US-20190225623-A1 SOLID FORMS OF A THIENOPYRIMIDINEDIONE ACC INHIBITOR AND METHODS FOR PRODUCTION THEREOF NIMBUS DISCOVERY, INC. 2019-07-25 — — US disclosed
US-10183951-B2 Solid forms of a thienopyrimidinedione ACC inhibitor and methods for production thereof GILEAD APOLLO, LLC (US) 2019-01-22 — — US disclosed
EP-3423456-A1 SOLID FORMS OF A THIENOPYRIMIDINEDIONE ACC INHIBITOR AND METHODS FOR PRODUCTION THEREOF Gilead Apollo, LLC (US) 2019-01-09 — — EP disclosed
US-20170267690-A1 SOLID FORMS OF A THIENOPYRIMIDINEDIONE ACC INHIBITOR AND METHODS FOR PRODUCTION THEREOF J.P. LAWSON CONSULTING LLC 2017-09-21 — — US disclosed
US-20170267690-A1 SOLID FORMS OF A THIENOPYRIMIDINEDIONE ACC INHIBITOR AND METHODS FOR PRODUCTION THEREOF J.P. LAWSON CONSULTING LLC 2017-09-21 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170267690-A1 SOLID FORMS OF A THIENOPYRIMIDINEDIONE ACC INHIBITOR AND METHODS FOR PRODUCTION THEREOF ACACA, ACACB, COASY ALDH1A1 164/4885RAB9A 4263/4885NPC1 1489/4885
US-11912718-B2 Solid forms of a thienopyrimidinedione ACC inhibitor and methods for production thereof ACACA, ACACB, COASY ALDH1A1 164/4885RAB9A 4263/4885NPC1 1489/4885
US-20200148699-A1 SOLID FORMS OF A THIENOPYRIMIDINEDIONE ACC INHIBITOR AND METHODS FOR PRODUCTION THEREOF ACACA, ACACB, COASY ALDH1A1 164/4885RAB9A 4263/4885NPC1 1489/4885
US-20220064181-A1 SOLID FORMS OF A THIENOPYRIMIDINEDIONE ACC INHIBITOR AND METHODS FOR PRODUCTION THEREOF ACACA, ACACB, COASY ALDH1A1 164/4885RAB9A 4263/4885NPC1 1489/4885
US-10183951-B2 Solid forms of a thienopyrimidinedione ACC inhibitor and methods for production thereof ACACA, ACACB, COASY ALDH1A1 164/4885RAB9A 4263/4885NPC1 1489/4885
US-20190225623-A1 SOLID FORMS OF A THIENOPYRIMIDINEDIONE ACC INHIBITOR AND METHODS FOR PRODUCTION THEREOF ACACA, ACACB, COASY ALDH1A1 164/4885RAB9A 4263/4885NPC1 1489/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.